Background/Objectives: Consumption of nÀ3 polyunsaturated fatty acids (PUFA) has a favourable impact on inflammation and cardiovascular disease. However, the Western diet is characterized by a low nÀ3 PUFA intake and an imbalance in the nÀ6/ nÀ3 PUFA ratio. Study the effect 10-week of diet modification to decrease the nÀ6/nÀ3 PUFA ratio on cardiovascular risk factors and resting energy expenditure. Conclusion: A decreased nÀ6/nÀ3 PUFA ratio can be achieved with simple dietary counselling, resulting in multiple, potentially favourable effects on the metabolic and inflammatory profiles.
Introduction
Over the last century, there has been a large increase in the consumption of nÀ6 polyunsaturated fatty acids (PUFA), such that in the Western diet the ratio of nÀ6 to nÀ3 fatty acids is E20-30:1, instead of the recommended range of E4-5:1 (Krauss et al., 2000; Kris-Etherton et al., 2002) . Recommendations for increased intake of nÀ3 fatty acids are based on their potential health benefits against cardiovascular disease including reduced mortality (GISSI-Prevenzione-Investigators, 1999; Simopoulos, 1999; Connor, 2000; Albert et al., 2002; Kris-Etherton et al., 2002) . Considering the evidence linking the progression of arteriosclerosis with lipid abnormalities and chronic inflammation, nÀ3 PUFAs may play an important preventive role via the modulation of these pathways (Pai et al., 2004) . Population-based studies have suggested a relationship between nÀ3 PUFA consumption and protection against cardiovascular events and coronary heart disease (Iso et al., 2006) . Beneficial effects for metabolic disorders such as obesity, insulin resistance and type 2 diabetes are speculative, but are supported by recent studies suggesting that nÀ3 PUFAs serve as important mediators of gene expression, potentially via peroxisome proliferator-activated receptors (PPARs) and/or sterol regulatory element-binding protein-1 (Simopoulos, 1999; Connor, 2000; Clarke, 2001; Summers et al., 2002; Ukropec et al., 2003; Delarue et al., 2004) . In most but not all cases, nÀ6 PUFA have opposite effects to those of nÀ3 PUFA. They also inhibit the formation of EPA (eicosapentaenoic acid, 20:5, nÀ3 PUFA) and DHA (docosahexaenoic acid, 22:6, nÀ3 PUFA) and their incorporation into cell membrane phospholipids (Gerster, 1998) .
Thus, a critical issue that must be addressed is how to effectively implement dietary recommendations for nÀ3 fatty acids. Furthermore, do such recommendations have measurable effects? Up to now, most studies have used fish oil supplementation, which is unlikely to be suitable for lifetime daily consumption and could have deleterious effects at very high doses (Simopoulos, 1999; Connor, 2000; Nettleton and Katz, 2005) . Perhaps, a more suitable way to increase nÀ3 fatty acid intake is to include 3-4 fatty fish meals in the weekly diet along with 20 g of vegetable oil rich in a-linolenic acid (ALA) (Kris-Etherton et al., 2000) . Ideally, this should be combined with a reduced intake of nÀ6 PUFA (Gerster, 1998) . To our knowledge, the effects of simultaneously increasing dietary intake of nÀ3 fatty acids and decreasing nÀ6 fatty acid intake have not been studied previously.
We hypothesized that increased nÀ3 PUFA consumption combined with a reduction in nÀ6 PUFA would have favourable outcomes. The objectives of this study were to assess the effects of this dietary modification on lipid, inflammatory and hormonal profiles, insulin sensitivity as well as resting energy expenditure in healthy subjects. The secondary objective was to investigate if appropriate intake and ratios of nÀ6/nÀ3 fatty acids could be achieved with simple dietary advice.
Subjects and methods

Subjects
Seventeen healthy subjects were recruited (10 males and 7 females; mean age 27.1 years (s.d. 1.9); mean body mass index (BMI) 22.4 kg/m 2 (s.d. 0.4)) through an advertisement for a dietary intervention study. The main inclusion criteria were: no first-or second-degree relatives with diabetes mellitus or obesity, BMI 20-25 kg/m 2 , age 18-60 years and a low usual intake of nÀ3 fatty acids (less than one fish meal per week, no intake of rapeseed, soya and walnut oil). None of the subjects had a history of hyperlipidaemia or inflammatory disease, and all were apparently healthy, as indicated by medical questionnaire, physical examination and routine laboratory analyses completed at enrolment. All subjects gave their written consent after being informed of the nature and purpose of the study as well as possible risks. The experimental protocol was approved by the ethics committee of Hospices Civils de Lyon and performed according to French legislation (Huriet law).
Diet and experimental design
The protocol consisted of a 10-week dietary intervention. The foods and ingredients selected for the diet were designed to increase the dietary content of nÀ3 fatty acids and to decrease nÀ6 fatty acids. Rapeseed oil was supplied with a daily intake of 20 ml (1.7 g/day of ALA). The study subjects were also instructed to augment their fish consumption to three fish meals per week (E100 g of salmon, tuna, mackerel, herring and sardines) in place of their habitual meat intake, providing a mean of 1.25 g/day of EPA and DHA. Advice was provided by a trained dietician twice before the dietary intervention and again after 1 month regarding the avoidance of foods containing high amounts of nÀ6 PUFA, vegetable oils (except rapeseed and olive) and their derivative products (potato chips, certain nuts and so on). Special emphasis was placed on qualitative but not quantitative modification of their habitual diet.
All subjects were given written and verbal instructions by a dietician on how to complete a 3-day (2 weekdays and 1 weekend day) dietary record before the initiation and during the last week of the dietary intervention. They also kept a food diary with daily rapeseed oil and fish intake. PUFA intakes were calculated using food composition tables specific to our country (CIQUAL table) (Deharveng et al., 1999) .
Advice was given on maintaining a constant physical activity level throughout the study.
The subjects underwent 2 days of testing before and at the end of the dietary intervention, including anthropometric measurements, blood samples, body composition and insulin sensitivity measurements. Each participant was invited to the Centre de Recherche en Nutrition Humaine de Lyon (CRNH), Hôpital Edouard Herriot, for a comprehensive series of tests following a 10-h overnight fast. After anthropometric measurements, catheters were installed to infuse D 2 -Glucose and to collect blood samples. Blood was drawn for the determination of fasting lipid, hormone and inflammatory profiles and erythrocyte membrane fatty acid composition, along with baseline clamp data. The resting metabolic rate was measured before and at the end of the clamp.
Weight and body composition
Body weight was recorded with the subject wearing no shoes and light clothing to the nearest 0.1 kg with an electronic Omega-3 fatty acids and adiponectin F Guebre-Egziabher et al scale. Height was measured to the nearest 0.5 cm. The waist/ hip ratio was calculated. Body composition was determined with a single-frequency bioelectrical impedance device (Star 50, Spengler, Cachan, France).
Euglycaemic hyperinsulinaemic clamp and indirect calorimetry
All patients underwent a 3-h euglycaemic hyperinsulinaemic (EH) clamp as described previously (Ducluzeau et al., 2001 ). An antecubital vein was cannulated for infusion of D 2 -Glucose (6,6-2 H 2 -glucose; Eurisotop, St-Aubain, France), 20% dextrose and insulin (Actrapid, Novo-Nordisk, Copenhagen, Denmark). The other arm was cannulated for blood sampling. A primed-constant infusion of D 2 -Glucose was begun 3 h before the start of insulin infusion to ensure isotopic equilibrium. After completion of the 3-h isotopic equilibration period, insulin was infused at the rate of 40 mU/kg.min for 180 min. Plasma glucose was measured every 10 min with a glucose analyser (Beckman Instruments, Fullerton, CA, USA) and maintained at a fasting level with a variable infusion rate of 20% dextrose. Blood was drawn each 10 min for the last 30 min of isotopic equilibrium, and EH clamp was undertaken for the determination of 6,6-2 H 2 -glucose isotopic enrichment, plasma glucose, insulin, free fatty acids, triacylglycerol and glycerol. Insulin sensitivity was calculated from the mean of four values obtained over 30 min (Rabasa-Lhoret et al., 2003) .
Continuous indirect calorimetry was performed with a ventilated hood system (Deltatrac, Datex Instruments Corp., Helsinki, Finland) during the last 60 min of tracer equilibrium and the EH clamp periods, for the measurement of carbohydrate and lipid oxidation rates (Laville et al., 1995) .
Erythrocyte membrane fatty acid composition Erythrocytes were obtained from a 4 ml blood sample collected in a tube containing 54 ml of EDTA 77 mM and centrifuged for 20 min at 200 g and 41C. The upper fraction rich in platelets was removed and the remaining lower fraction was treated with 1 ml NaCl 9% and 1 ml of EDTA. A volume of 1 ml Dextran 5% was added and the tube was left to settle at lab temperature. The base was then washed successively with 1 ml of a Tyrode Hepes buffer at pH 7.4 and 2 Â 1 ml of NaCl 9%. An additional centrifugation at 1800 g for 10 min isolated erythrocytes, and 40 ml of BHT 1 mM was added to avoid PUFA oxidation.
Heptadecanoic acid was added as an internal standard and lipids from this fraction were extracted by the method of Bligh and Dyer (Bligh and Dyer, 1959) , followed by transesterification with BF 3 -methanol at 1001C. The crude fatty acid methyl ester (FAME) mixture was purified by thin-layer chromatography (hexane, diethyl ether, acetic acid, 80:20:1). The FAME spot scraped from silica was reconstituted in 250 ml of trimethylpentane. Chromatographic separation of FAME was achieved with a capillary column (HP Innowax 60 m Â 0.25 mm Â 0.25 mM) after a 1-ml pulsed, splitless injection (splitless time: 1 min; pulse pressure: 35 psi). Helium was used as a carrier gas at a constant flow rate of 1.2 ml/min (24 psi at 901C). Oven temperature was started at 901C for 1 min, then raised to 1751C at 151C/min, followed by a 51C/min increase to 2251C (10 min), and finally up to 2551C at 101C/min and maintained at this temperature for 10 min. Electron impact mass spectrometry was undertaken in an HP5973 MSD (Agilent Technologies, Massy, France) working at 70 eV, in full-scan detection for fatty acid profiles. Fatty acids were measured against one calibration point from a standard mixture of the most important components from Supelco (Sigma Aldrich, St-Quentin Fallavier, France) relative to heptadecanoic acid methyl ester.
Laboratory analyses
Plasma glucose was quantified by the glucose oxidase method (Beckman Instruments, Fullerton, CA, USA), and free fatty acids were measured by the colorimetric enzymatic method (Wako Pure Chemical Industry, Neuss, Germany). Plasma triacylglycerols, glycerol and beta-hydroxybutyrate were analysed according to enzymatic methods (Laville et al., 1995) .
Plasma isotopic enrichment of 6,6-2 H 2 -glucose was assessed by gas chromatography-mass spectrometry (HP 5971 MSD, Hewlett Packard, Palo Alto, CA, USA), and glucose turnover rates were calculated by steady-state equations (Laville et al., 1995) .
The serum concentrations of leptin, adiponectin, tumour necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6) were measured in duplicate by enzyme-linked immunosorbent assay (with Quantikine leptin, Quantikine high sensitivity TNF-a and Quantikine IL-6, kits from R&D Systems, Oxford, UK, and adiponectin kit from BioCat, Heidelberg, Germany). Plasma insulin was quantified in duplicate by radioimmunoassay (Ins Irma, Kip 1251, MDS Nordion, France). C-reactive protein (CRP) was assessed by immunonephelometry in an IMAGE analyser (Beckman-Coulter, Villepinte, France).
Statistical methods
All values are presented as mean (s.d.). Paired t-tests and the Wilcoxon rank test were performed for comparisons between final and baseline values or percentage variations from baseline when applicable. Data analyses were undertaken using Statview statistical software program (Statview, version 5.0, SAS Institute Inc., Cary, NC, USA). P-values less than 0.05 were considered statistically significant.
Results
Subjects and diet diaries
The anthropometric and body composition values of the study subjects did not change significantly during the period of the trial, and there were no subject withdrawals (Table 1) .
Omega-3 fatty acids and adiponectin F Guebre-Egziabher et al Dietary intake was estimated by analysing the diet diaries before and during the last week of the dietary intervention. Initial intake met the inclusion criteria (high nÀ6 PUFA intake, low nÀ3 PUFA intake, linoleic acid (LA)/ALA ratio: 32.2 (s.d. 15.4), Table 2 ). Compliance with the dietary intervention was good, with no modification of energy and constant macronutrient intake. During the intervention, subjects markedly increased their fish intake (22.9711 vs 305.41 g/week, P ¼ 0.0003).
As expected, ALA intake increased significantly and LA intake decreased, lowering the LA/ALA ratio to 2.2 (s.d. 0.3) (Po0.0001). The high percentage of oleic acid (63% of C18:1) in rapeseed oil explains the significant elevation of monounsaturated fatty acids (MUFA). The dietary intervention was also associated with a significant reduction in saturated fat intake (Table 2) .
Total fatty acid composition was ascertained in the erythrocyte membranes in all subjects. After 10 weeks of dietary intervention, EPA (C20:5 nÀ3 PUFA) rose significantly from 0.96 to 1.50% (P ¼ 0.008), with a concomitant increase in the nÀ3/nÀ6 PUFA ratio from 0.25 to 0.33 (P ¼ 0.01). No concomitant change in the content of nÀ6 fatty acids was apparent in erythrocytes (Table 3) .
Hormonal and inflammatory profiles
Mean plasma adiponectin rose significantly after the 10-week diet (baseline: 6.50 mg/ml (s.d. 0.70) vs post-intervention: 7.63 mg/ml (s.d. 0.62), P ¼ 0.02, Figure 1a ). Plasma leptin concentration was in the normal range, and did not change significantly (9.16 ng/ml (s.d. 2.58) vs 8.39 ng/ml (s.d. 2.79), respectively). Plasma TNF-a concentration declined significantly after 10 weeks (2.18 pg/ml (s.d. 0.34) vs 1.50 pg/ml (s.d. 0.32), P ¼ 0.01, Figure 1b) , whereas the decreases in IL-6 
Lipid profile
In the fasting state, the diet induced a significant reduction in low-density lipoprotein (LDL)-cholesterol, whereas there was a non-significant reduction in total cholesterol and glycerol (Table 4) . No significant differences were observed under hyperinsulinaemic conditions (Table 5) .
Substrate utilization, glucose homeostasis and insulin sensitivity The resting metabolic rate was not affected by the dietary intervention (data not shown). However, the 10-week programme had a substantial effect on substrate utilization. Table 4 ). Neither fasting glucose nor plasma insulin was affected by the dietary intervention (Table 4) . At the end of the EH clamp, the decrease in the glucose oxidation rate remained statistically significant (3.6 mg/kg.min (s.d. 0.7) vs 3.3 mg/kg.min (s.d. 0.6), P ¼ 0.04). Insulin sensitivity, as estimated by the EH clamp (Table 5) , was not modified significantly.
Discussion
The present study shows that a nutritional intervention consisting of simple dietary recommendations focusing on the dietary nÀ6/nÀ3 PUFA ratio has a favourable metabolic impact including a decrease in LDL-cholesterol, and increases in lipid oxidation and plasma adiponectin. Furthermore, plasma TNF-a (Figure 1 ) was significantly decreased in agreement with previously reported reductions in ex vivo TNF-a production in mononuclear cells after supplementation with encapsulated fish oil (Endres et al., 1989; Meydani et al., 1991; Caughey et al., 1996; Wigmore et al., 1997) .
In contrast to other adipocyte-derived molecules such as TNF-a, adiponectin has been proposed to have protective metabolic and anti-inflammatory properties that could be associated with lower risk of cardiovascular disease (Skilton and Celermajer, 2006) . The observed increase in adiponectin levels is consistent with both cross-sectional reports of an inverse correlation between adiponectin and inflammatory mediators in obese subjects (Engeli et al., 2003) , and inverse associations with TNF-a levels in human adipose tissue (Kern et al., 2003) . Furthermore, the increase in adiponectin is consistent with investigations in mice showing that the consumption of a diet rich in EPA and DHA leads to elevated systemic adiponectin concentration (Flachs et al., 2006; Neschen et al., 2006) .
Another important finding of the present work was the impact of the diet on substrate utilization in both fasting and hyperinsulinaemic conditions (Tables 4 and 5 ). The diet increased lipid oxidation in the fasting state, as already reported with higher supplementation (6 g/day of fish oil for 6 weeks) in healthy humans (Couet et al., 1997) . Such effects of nÀ3 PUFA on lipid oxidation can modify total fat mass (Couet et al., 1997) , and prevent or partially reverse the fat mass accumulation associated with high-sucrose, highfructose or high-fat diets in animals (Halvorsen et al., 2001; Lombardo and Chicco, 2006) . However, we found no change in body composition, but the magnitude of changes in body fat previously reported (o1 kg of fat mass in 6-8 weeks) was within the variability of the method used in the present study. Moreover, the subjects in this study had normal fat mass at baseline (Table 1) .
Epidemiological and interventional studies indicate that the quality of dietary fat influences insulin sensitivity in humans (Rivellese and Lilli, 2003) . In particular, saturated fatty acids worsen insulin sensitivity, while MUFA and nÀ6 PUFA cause improvements. The impact of nÀ3 PUFA is less clear. In the present study, using the gold standard for the determination of insulin sensitivity, we saw no significant effect on insulin sensitivity in healthy, young, non-obese adults (Table 5) , despite a modest increase in adiponectin. Omega-3 fatty acids and adiponectin F Guebre-Egziabher et al
In contrast, most studies that have reported a relationship between insulin sensitivity and adiponectin concentration have included insulin-resistant subjects (Weyer et al., 2001; Rivellese and Lilli, 2003) . Many previous studies have used encapsulated fish oil supplements (Simopoulos, 1999; Connor, 2000; Nettleton and Katz, 2005; Hooper et al., 2006) , which are unlikely to be suitable for long-term use. In the present experiment, we were able to demonstrate that a simple dietary intervention markedly reduced the nÀ6/nÀ3 PUFA ratio, assessed by both diet diary and erythrocyte membrane fatty acid concentration (Tables 2 and 3 ). This is consistent with the data from the Omega Diet (Simopoulos and Robinson, 1999) and the Swedish study (Friberg and Johansson, 2007) .
Increased MUFA intake, reduced saturated fat intake or changes in other components of fish and/or oil could also have contributed to the observed results, either by themselves or through interaction with nÀ3 PUFA (He and Daviglus, 2005; Hooper et al., 2006) . Such dietary modifications are part of the Mediterranean diet, which has been shown to be highly effective in the secondary prevention of coronary heart disease (de Lorgeril et al., 1999) . From a public health perspective, it is interesting to demonstrate that this simple advice on PUFA intake is able to bring about a more globally favourable dietary modification.
Mechanisms that may underlie our observations include nÀ3 PUFA modifying key genes involved in fatty acid oxidation, including acetyl-CoA carboxylase, fatty acid synthase, carnitine palmitoyltransferase 2 and peroxisomal fatty acid oxidase (Jump and Clarke, 1999; Baker and Gibbons, 2000) , and modulating adiponectin expression through AMP-activated kinase activation (Flachs et al., 2006) , or interaction with PPAR-g (Neschen et al., 2006) . These increases in adiponectin may subsequently upregulate genes involved in fatty acid oxidation (Yamauchi et al., 2002; Rossi et al., 2005) .
The present study has some limitations. No control group was included and the sample size was small. Thus, while our findings provide preliminary evidence for an effect of the nÀ6/nÀ3 PUFA ratio on plasma adiponectin and lipid oxidation, these results require confirmation in larger, controlled trials.
Our results support an impact of nÀ6/nÀ3 PUFA ratio change at various levels, including favourable anti-inflammatory and lipid profiles. The observed modulation of adiponectin and cytokine levels by a simple nutritional approach independent of changes in body weight, if confirmed among obese and insulin-resistant subjects, would represent an attractive approach in terms of the prevention of diabetes and cardiovascular disease.
